Seer (SEER) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 Jul, 2026Executive summary
Board urges shareholders to vote for its seven director nominees amid a contested proxy fight with the Radoff-JEC Group, which seeks to replace three directors with its own candidates.
Board letter refutes claims by Radoff and Torok regarding company performance, governance, and executive compensation, emphasizing long-term value creation.
Highlights Seer's strong cash position, reduced cash burn by 36% since 2022, and ongoing investments in platform commercialization.
Board asserts that the activist group’s agenda is short-term focused, aiming for a quick sale and cash extraction, which could undermine long-term shareholder value.
Voting matters and shareholder proposals
Shareholders are asked to vote on the election of seven board nominees at the July 28, 2026 Annual Meeting, with the Board recommending a vote for its slate on the BLUE proxy card.
The proxy contest centers on whether to support the Board’s nominees or those proposed by the Radoff-JEC Group.
Board of directors and corporate governance
Board consists of qualified, independent directors, including Omid Farokhzad, Meeta Gulyani, Robert Langer, Terrance McGuire, Dipchand Nishar, Isaac Ro, and Nicolas Roelofs.
Board refutes allegations of lack of independence and highlights ongoing engagement with shareholders, including six meetings with Radoff and Torok since late 2024.
Board emphasizes that no board decisions have been impacted by independence concerns.
Latest events from Seer
- Shareholders are urged to support current directors in a contested board election for continued progress.SEER
Proxy filing22 Jul 2026 - Independent directors unanimously rejected a CEO-led acquisition proposal as undervaluing the company.SEER
Proxy filing20 Jul 2026 - Board urges support for its director nominees to ensure long-term value and strategic growth.SEER
Proxy filing20 Jul 2026 - Board urges support for its nominees to ensure strategic growth and protect shareholder value.SEER
Proxy filing20 Jul 2026 - Board urges support for its nominees to protect long-term value and resist dissident takeover.SEER
Proxy filing14 Jul 2026 - Rapid innovation, global expansion, and strong financials drive leadership in unbiased proteomics.SEER
43rd Annual J.P. Morgan Healthcare Conference 20258 Jul 2026 - 2025 revenue is guided to grow 24% amid strong adoption, innovation, and robust cash reserves.SEER
Q4 20248 Jul 2026 - Q2 revenue fell 23% to $3.1M; guidance cut and $3.7M in shares repurchased amid headwinds.SEER
Q2 20248 Jul 2026 - Vote for the seven incumbent directors to protect long-term value and strategic direction.SEER
Proxy filing8 Jul 2026